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cells) in 7 TET WHO C (70%, including the paired primary/second-
ary tumor), a mild expression (1+ positivity on 100% of the cell) was 
observed in 2 TET WHO C, 1 TET WHO C was c-kit negative, all the 
A, AB, B1-3 WHO subtypes were negative. A nuclear HER2 staining 
was observed for 1 TET WHO A, 2 TET WHO AB, 3 TET WHO B2, 2 
TET WHO B3, and 1 micronodular TET. The 2 carcinoid tumors were 
strongly positive for c-kit and negative for CD20 and HER2.
Conclusions: CD20 and c-kit expression are restricted to TET WHO 
AB and C respectively. HER2 nuclear staining pattern is of unknown 
signiﬁcance. VEGFR 1-2 data will be presented at the meeting.
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Background: Platelet-type 12-Lipoxygenase is an arachidonic acid 
metabolising enzyme that results in the formation of 12(S)-HETE. 
12(S)-HETE is proangiogenic, and has been shown to stimulate tumour 
cell adhesion, invasion and metastasis. Inhibitors of 12-LOX are cur-
rently undergoing extensive investigation, and a detailed examination of 
the effects of these agents in lung cancer is warranted. In this study we 
examined the expression proﬁle of 12-LOX in human lung cancer cell 
lines and resected tissue. We also examined the mechanisms responsible 
for apoptosis following selective inhibition of 12-LOX with baicalein. 
Methods: A549 (adenocarcinoma), SK-MES1 (squamous cell lung 
carcinoma), H460 and H647 (large cell lung carcinoma) were grown 
in serum depleted media (0.5%) and screened for 12-LOX expression 
by RT-PCR and western blot analysis. Cells were treated with baicalein 
(10uM), a selective inhibitor of 12-LOX, or 12(S)-HETE (100ng/ml) 
and cell survival / proliferation determined by BrdU assay. Apoptosis 
was determined using the multi-parameter apoptosis kit and In-cell 
Analyser, DNA laddering and also by FACS. Gene alterations follow-
ing 12-LOX inhibition in both A549 and SKMES-1 cells were assessed 
by quantitative PCR arrays and validated by RT-PCR. A panel of retro-
spective resected lung tumours were stained for 12-LOX expression by 
immunhistochemistry. 
Results: All lung cancer cells lines expressed moderate levels of plate-
let-type 12-LOX, which was reduced following treatment for 24h with 
increasing concentrations of baicalein. Baicalein decreased lung cancer 
survival in all cell lines, while 12(S)-HETE increased cellular prolif-
eration. Inhibition of 12-LOX induced apoptosis in a dose dependent 
manner, with decreased f-actin ﬁlaments and loss of mitochondrial 
mass potential. Induction of apoptosis was also conﬁrmed by DNA 
laddering and Annexin-V FACS labelling. QPCR array data implicated 
a number of genes regulating these effects which were validated by RT-
PCR, many of which control apoptosis and angiogenesis. The subset 
of genes downregulated included bcl-2, VEGF, integrin α2 and α4. 
12-LOX expression was observed in a variety of human lung cancers 
with different histological subtypes. We are currently silencing 12-LOX 
expression in these cells, using shRNA technology, to further examine 
these mechanisms.
Conclusions: 12-LOX is a survival factor in NSCLC. 12-LOX inhibi-
tion decreased NSCLC survival, inducing apoptosis through mecha-
nisms including downregulation of the bcl family of proteins, integrin 
receptor and angiogenic growth factors. Expression of 12-LOX in fresh 
resected and retrospective tissue suggests that inhibition of this enzyme 
is a potential therapeutic strategy in the treatment of NSCLC.
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Background: Abberant DNA methylation, including hypermethylation 
of tumor suppressor genes or hypomethylation of oncogenes, is a hall-
mark of cancer and can be found in almost all cancer types. Informa-
tion about which methylation events are disease speciﬁc and also have 
effect on gene expression has a great potential in diagnostics and drug 
development. The aim of this study was to investigate the methylation 
status of the tumor suppressor genes SHP1, SHP2, SOCS1 and SOCS3 
and the transcription factor STAT1, and its effect on protein expression 
and tumor biology in lung cancer cell lines. Their activities are required 
for a functional regulation of cell growth and these genes have previ-
ously shown hypermethylation-associated tumor occurrence in several 
other types of cancers.
Methods: To study methylation patterns, bisulﬁte treatment of total 
DNA followed by PCR ampliﬁcation and Pyrosequencing® analysis 
was employed. The gene regions to be analyzed were determined ac-
cording to the regions that previously had shown aberrant methylation 
patterns in other types of cancers and psoriasis. Expression levels of the 
different proteins were evaluated by immunoprecipitation using anti-
bodies directed against each protein, followed by SDS-Polyacrylamide 
Gel Electrophoresis (SDS-PAGE) and Western blotting.
Five NSCLC cell lines and ﬁve SCLC were used in the studies.
Results: The methylation studies showed that the genes SHP1, SOCS1 
and SOCS3 are strongly methylated in some of the analyzed lung 
cancer (LC) cell lines, whereas SHP2 and STAT1 were not signiﬁcantly 
methylated in any cell line. The protein expression studies showed 
that the observed methylation levels in SHP1 were associated with a 
reduction of protein expression in the LC cell lines. Furthermore, the 
promoter region 1 (SHP1 A) of SHP1 demonstrated varying degrees of 
methylation throughout the LC cell lines, whereas promoter region 2 
(SHP1 B and C) was highly methylated in all cell lines. The epigenetic 
regulation of SHP1 has earlier been attributed to promoter region 2. 
In this study, on the other hand, the reduced protein expression seems 
to be associated with methylation in promoter region 1. SHP1 has 
earlier been reported to be methylated in promoter region 2 in normal 
epithelial cells, but to our knowledge there have been no reports on 
methylation in promoter region 1. The importance of the reduced SHP1 
expression in the regulation of proliferation, migration and invasion 
are being analyzed in the lung cancer cell lines and further data will be 
presented at the meeting.
Conclusions: The tumor suppressor genes SHP1, SOCS1 and SOCS3 
are highly methylated in lung cancer cell lines, making them potential 
diagnostic markers for lung cancer. Furthermore, methylation of the 
SHP1 promoter region 1 is associated with a strongly reduced protein 
